Homologous recombination repair capacity in peripheral blood lymphocytes and breast cancer risk.

Carcinogenesis
Jie ShenHua Zhao

Abstract

Deficiency in homologous recombination repair (HRR) capacity is frequently observed in breast tumors. However, whether HRR deficiency is a tumor-specific biomarker or a risk factor for breast cancer is unknown. In this two-stage study, using a host cell reactivation assay, we assessed the relationship between HRR capacity in peripheral blood lymphocytes (PBLs) and breast cancer risk. The discovery stage included 152 breast cancer patients and 152 healthy controls matched on age and race. HRR capacity was found to be significantly lower in Black women than in White women among controls (P = 0.015) and cases (P = 0.012). Among cases, triple negative breast cancer patients had significantly lower HRR capacity than ER+/PR+ breast cancer patients (P = 0.006). In risk assessment, HRR capacity was found to be significantly lower in cases than in controls (P < 0.001), and decreased HRR capacity was associated with 1.42-fold increased risk of breast cancer (95% CI: 1.21, 2.53). In the validation stage, we assessed HRR capacity in a nested case-control study using pre-diagnostic samples. We found that decreased HRR capacity was associated with 1.21-fold increased risk of breast cancer (95% CI: 1.04, 4.58). In summary, our results demonst...Continue Reading

References

Oct 25, 2003·Science·Mary-Claire KingUNKNOWN New York Breast Cancer Study Group
Jan 20, 2005·Journal of the National Cancer Institute·David O KennedyRegina M Santella
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jie LinXifeng Wu
Mar 17, 2007·DNA Repair·Thomas HelledayBevin P Engelward
Oct 8, 2014·Nature Reviews. Clinical Oncology·Amir SonnenblickMartine Piccart
Apr 3, 2015·Cold Spring Harbor Perspectives in Biology·Rohit PrakashMaria Jasin
May 8, 2018·Breast Cancer Research and Treatment·M L TelliE P Winer
Feb 5, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R CondorelliN C Turner
Feb 6, 2019·Breast Cancer : Targets and Therapy·Sumadee De SilvaEric Hamilton Karunanayake
Aug 21, 2019·NPJ Breast Cancer·Anqi LiJorge S Reis-Filho

❮ Previous
Next ❯

Citations

Oct 27, 2021·Aging·Hua ZhaoJie Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.